In a report released today, Garik Shmois from Loop Capital Markets maintained a Buy rating on Carlisle Companies (CSL –Research Report), with a price target of $475.00. The company’s shares closed yesterday at $420.30. Maximize Your Portfolio with Data Driven Insights: Leverage the power of...
About FILSPARI (sparsentan) FILSPARI (sparsentan) is a once-daily, oral medication designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II) and is the first and only non-immunosuppressive therapy approved for the treatment of this ...
The transaction, has been unanimously approved by both companies’ Boards of Directors. The offer price for each registered share of Vifor Pharma Ltd. is USD 179.25 in cash. The public tender offer is subject to the offer conditions set forth in the offer prospectus, which includes the report ...
Revenue Per Share 0.79 0.97 0.86 -0.25 0.43 Ebit Per Revenue 0.27 0.46 0.14 0.27 0.43 Click cells to compare fundamentalsCarlisle Revenue Historical Pattern Today, most investors in Carlisle Companies Stock are looking for potential investment opportunities by analyzing not only static indicators but ...